{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IL-2&page=21", "query": { "intervention": "IL-2", "page": 21 }, "page_size": 10 }, "pagination": { "page": 21, "page_size": 10, "total_count": 671, "total_pages": 68, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IL-2&page=22&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IL-2&page=20&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T05:00:50.533Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01106950", "title": "Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia, Myelogenous, Acute" ], "interventions": [ { "name": "Natural Killer Cells", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Denileukin diftitox", "type": "DRUG" }, { "name": "Donor lymphapheresis", "type": "PROCEDURE" }, { "name": "IL-2", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 15, "start_date": "2010-07", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2017-12-28", "last_synced_at": "2026-10-20T05:00:50.533Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01106950" }, { "nct_id": "NCT06096090", "title": "Phase II Clinical Trial of Interleukin-2 in AD", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alzheimer Disease" ], "interventions": [ { "name": "Interleukin-2", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Methodist Hospital Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "86 Years", "sex": "ALL", "summary": "50 Years to 86 Years" }, "enrollment_count": 40, "start_date": "2022-01-01", "completion_date": "2025-12-30", "has_results": false, "last_update_posted_date": "2024-05-23", "last_synced_at": "2026-10-20T05:00:50.533Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06096090" }, { "nct_id": "NCT06318871", "title": "Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Renal Carcinoma", "Renal Cell Carcinoma", "Urothelial Carcinoma", "Chromophobe Renal Cell Carcinoma", "Translocation Renal Cell Carcinoma" ], "interventions": [ { "name": "Cytokine Induced Memory-like Natural Killer (CIML NK) Cells", "type": "BIOLOGICAL" }, { "name": "Interleukin-2 (IL-2)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2024-08-28", "completion_date": "2031-07-28", "has_results": false, "last_update_posted_date": "2026-05-11", "last_synced_at": "2026-10-20T05:00:50.533Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06318871" }, { "nct_id": "NCT07049328", "title": "HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Alopecia Areata(AA)" ], "interventions": [ { "name": "HCW9302, an IL-2 fusion protein", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "HCW Biologics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 30, "start_date": "2025-08-16", "completion_date": "2027-12-15", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-20T05:00:50.533Z", "location_count": 3, "location_summary": "Tampa, Florida • Indianapolis, Indiana • Columbus, Ohio", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07049328" }, { "nct_id": "NCT00015652", "title": "Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections", "Hepatitis C" ], "interventions": [ { "name": "Ribavirin", "type": "DRUG" }, { "name": "Aldesleukin", "type": "DRUG" }, { "name": "Peginterferon alfa-2b", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 24, "start_date": null, "completion_date": "2005-03", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-10-20T05:00:50.533Z", "location_count": 8, "location_summary": "Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00015652" }, { "nct_id": "NCT02111863", "title": "Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Skin Cancer" ], "interventions": [ { "name": "Aldesleukin", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "4-1BB Selected Tumor Infiltrating Lymphocytes (TIL)", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 6, "start_date": "2014-02-21", "completion_date": "2016-07-21", "has_results": true, "last_update_posted_date": "2017-09-19", "last_synced_at": "2026-10-20T05:00:50.533Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02111863" }, { "nct_id": "NCT05395052", "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Small Cell Lung Cancer", "Colorectal Cancer", "Breast Cancer", "Ovarian Cancer", "Pancreatic Cancer", "Head and Neck Cancer", "GastroEsophageal Cancer" ], "interventions": [ { "name": "FT536", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "IL-2", "type": "DRUG" }, { "name": "Avelumab", "type": "COMBINATION_PRODUCT" }, { "name": "Pembrolizumab", "type": "COMBINATION_PRODUCT" }, { "name": "Nivolumab", "type": "COMBINATION_PRODUCT" }, { "name": "Atezolizumab", "type": "COMBINATION_PRODUCT" }, { "name": "Trastuzumab", "type": "COMBINATION_PRODUCT" }, { "name": "Cetuximab", "type": "COMBINATION_PRODUCT" }, { "name": "Amivantamab", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2022-05-31", "completion_date": "2023-08-11", "has_results": false, "last_update_posted_date": "2023-09-21", "last_synced_at": "2026-10-20T05:00:50.533Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Hackensack, New Jersey + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05395052" }, { "nct_id": "NCT00337987", "title": "A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Peripheral T-Cell Lymphoma" ], "interventions": [ { "name": "Ontak", "type": "DRUG" }, { "name": "CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2005-11", "completion_date": "2008-01", "has_results": true, "last_update_posted_date": "2015-02-27", "last_synced_at": "2026-10-20T05:00:50.533Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00337987" }, { "nct_id": "NCT00019916", "title": "Vaccine Therapy Plus Interleukin-2 in Treating Women With Stage IV, Recurrent, or Progressive Breast or Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Ovarian Cancer" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "p53 peptide vaccine", "type": "BIOLOGICAL" }, { "name": "in vitro-treated peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": null, "start_date": "2000-06", "completion_date": "2006-07", "has_results": false, "last_update_posted_date": "2013-06-20", "last_synced_at": "2026-10-20T05:00:50.533Z", "location_count": 2, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00019916" }, { "nct_id": "NCT00016237", "title": "Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bladder Cancer", "Kidney Cancer", "Lung Cancer" ], "interventions": [ { "name": "tucotuzumab celmoleukin", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "EMD Serono", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-10-23", "last_synced_at": "2026-10-20T05:00:50.533Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • New York, New York", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00016237" } ] }